Drugs targeting the human epidermal growth factor receptor-2 (HER2) have revolutionized the treatment landscape of HER2-positive breast cancer (BC) patients, creating a new standard of remarkable survival outcomes for once a BC subtype with gloomy perspectives [1,2,3,4,5]. The gene discussed is ERBB2; the disease is breast cancer.